Acquisition will give Pfizer access to crisaborole, a non-steroidal topical gel currently under review by the FDA
Pfizer is buying Anacor Pharmaceuticals in a $5.2bn (£3.6bn) deal to add an eczema gel to its portfolio, just a month after the US drug major scrapped plans to acquire Allergan.
Anacor shares surged by as much as 56% to $99.94 on Monday, above the offer price of $99.25 per share in cash. The net-of-cash deal value assumes conversion of Anacor’s outstanding convertible notes, the companies said in a statement.
Related: Pfizer death penalty drug decision welcomed by activists but states fight on
Continue reading...from Mergers and acquisitions | The Guardian http://ift.tt/1ssneBJ
No comments:
Post a Comment